The study is evaluating graphene-based brain–computer interfaces (BCIs) in human patients, marking the world’s first clinical study to assess a graphene device in direct contact with the human nervous system. This technology, developed at ICN2, has already shown promising initial results in both safety and its ability to detect and stimulate neuronal activity.
Patient enrolment of the first-in-human trial designed to clinically translate a graphene-based brain–computer interface originally developed at ICN2 has been completed. This technology represents a significant step forward in the fields of neurotechnology and precision medicine.
The clinical trial, which began in 2024, sponsored by the University of Manchester in the UK using devices by INBRAIN Neuroelectronics, a spin-off company from ICN2 and CSIC, has aimed to demonstrate primarily the safety of the device. In addition, it seeks to evaluate other key parameters, such as the ability of these electrodes to accurately detect and modulate brain activity, as well as their compatibility with surgical instruments. A total of ten patients have been recruited, eight of whom have undergone procedures using the device during brain tumour resection surgeries. These interventions were clinically led by neurosurgeon Dr David Coope at NHS Salford Royal Hospital, part of the Manchester Centre for Clinical Neurosciences.
As explained by ICREA Prof. Kostas Kostarelos, Group Leader at ICN2 and Co-Founder of INBRAIN, the results obtained so far are highly encouraging: “no device-related adverse events have been reported during the procedures or up to the patients’ discharge from hospital. Beyond safety, the study has also enabled validation of the system’s performance under real surgical conditions. In this context, the ultrathin and flexible graphene electrodes have demonstrated high-resolution neural signal detection and improved adaptation to the brain surface compared to conventional metallic electrodes.” In some procedures performed with awake patients, tasks such as object naming were carried out to map brain activity associated with language.
These findings reinforce the clinical potential of this technology, which stems from cutting-edge research by the ICN2 Advanced Electronic Materials and Devices Group, led by ICREA Prof. Jose A. Garrido and the Nanomedicine Lab, led by Prof. Kostarelos. While the final results of the study are still pending and expected by the end of this year, graphene-based electrodes are already emerging as a key tool for improving surgical precision and brain activity mapping. In parallel, earlier-stage studies are underway to explore their potential in the treatment of neurodegenerative disorders such as Parkinson’s disease.
This milestone also marks an important step in the clinical pathway of a technology developed at ICN2 and highlights the Institute’s impact in translating frontier research into innovative solutions with real application in medical practice. The final results of the study are expected by the end of 2026.